[1] Vue D, Tang QY. Zika virus overview: transmission, origin, pathogenesis, animal model and diagnosis. Zoonoses (Burlingt), 2021; 1.
[2] Zhou KH, Li CQ, Shi W, et al. Current progress in the development of Zika virus vaccines. Vaccines (Basel), 2021; 9, 1004. doi:  10.3390/vaccines9091004
[3] Reynolds CJ, Suleyman OM, Ortega-Prieto AM, et al. T cell immunity to Zika virus targets immunodominant epitopes that show cross-reactivity with other Flaviviruses. Sci Rep, 2018; 8, 672. doi:  10.1038/s41598-017-18781-1
[4] Priyamvada L, Quicke KM, Hudson WH, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA, 2016; 113, 7852−7. doi:  10.1073/pnas.1607931113
[5] Endale A, Medhin G, Darfiro K, et al. Magnitude of antibody cross-reactivity in medically important mosquito-borne flaviviruses: a systematic review. Infect Drug Resist, 2021; 14, 4291−9. doi:  10.2147/IDR.S336351
[6] Balz K, Trassl L, Härtel V, et al. Virus-induced T cell-mediated heterologous immunity and vaccine development. Front Immunol, 2020; 11, 513. doi:  10.3389/fimmu.2020.00513
[7] Rivino L, Lim MQ. CD4+ and CD8+ T-cell immunity to Dengue–lessons for the study of Zika virus. Immunology, 2017; 150, 146−54. doi:  10.1111/imm.12681
[8] Mapalagamage M, Weiskopf D, Sette A, et al. Current understanding of the role of T cells in chikungunya, dengue and Zika infections. Viruses, 2022; 14, 242. doi:  10.3390/v14020242
[9] Terzian ACB, Schanoski AS, de Oliveira Mota MT, et al. Viral load and cytokine response profile does not support antibody-dependent enhancement in dengue-primed Zika virus–infected patients. Clin Infect Dis, 2017; 65, 1260−5. doi:  10.1093/cid/cix558
[10] de Góes Cavalcanti LP, Tauil PL, Alencar CH, et al. Zika virus infection, associated microcephaly, and low yellow fever vaccination coverage in Brazil: is there any causal link? J Infect Dev Ctries, 2016; 10, 563−6. doi:  10.3855/jidc.8575